Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31338904 | 0.86 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL4764351 | 0.84 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL17157479 | 0.83 | ALDH1A3 (0.53) | ALDH1A1SMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL5523809 | 0.82 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL28485507 | 0.81 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL17864851 | 0.80 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL4765870 | 0.79 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL15853563 | 0.77 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2NPC1MAPTHTT | |
| SCHEMBL13145347 | 0.77 | PRKCI (0.38) | ALDH1A1NPC1MAPTHTTRAB9A | |
| SCHEMBL4771689 | 0.76 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2NPC1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023066348-A1 | DUAL ANTAGONIST AND USE THEREOF | 年衍药业（上海）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| EP-3708163-A1 | USE OF SPARSENTAN FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Ligand Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3708163-A1 | USE OF SPARSENTAN FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Ligand Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3222277-B1 | A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS AND IGA-INDUCED NEPHROPATHY | LIGAND PHARM INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20180344705-A1 | METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | LIGAND PHARMACEUTICALS INC. | 2018-12-06 | — | — | US | disclosed |
| US-9993461-B2 | Method for treating disorders associated with glomerular function | LIGAND PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993461-B2 | Method for treating disorders associated with glomerular function | LIGAND PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-12-14 | — | — | US | disclosed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1237888-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6852745-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-6835741-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885SMN1; SMN2 3448/4885NPC1 3810/4885 |
| US-20180344705-A1 | METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | AGTR2, AGTR1, EDNRA | ALDH1A1 1107/4885SMN1; SMN2 3564/4885NPC1 1760/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885SMN1; SMN2 3448/4885NPC1 3810/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885SMN1; SMN2 3448/4885NPC1 3810/4885 |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | REN, AGTR2, AGTR1 | ALDH1A1 1720/4885SMN1; SMN2 3173/4885NPC1 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.